Minimal change disease associated with IgA nephropathy “a rare clinical spectrum”: Case report
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication is free and its contents are distributed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND 4.0). The rights of the works published in this journal are property of the author and they are free to distribute and disseminate the same sources as long as he correctly cites the font of publication, these acts are not for commercial purposes and no derivative works are generated.
Main Article Content
Abstract
Minimal change disease (MCD) is one of the main causes of idiopathic nephrotic syndrome, manifesting with intense proteinuria leading to edema and intravascular volume depletion, characterized by the absence of alterations in light microscopy and the presence of effacement of the podocyte processes in electron microscopy. Although the cause is unknown, it is believed that due to an immunologic dysregulation and modifications of the podocyte and of the proteins that constitute the cytoskeleton of this one and of the filtration diaphragm, generating an alteration in the integrity of the glomerular basement membrane and, therefore, conditioning the presence of proteinuria. IgA nephropathy (IgAN) is the most common mesangial proliferative glomerulopathy in developed countries and one of the main causes of chronic kidney disease and renal failure in Asian population, characterized by the presence of mesangial IgA deposits. The clinical presentation is extremely variable, ranging from isolated dysmorphic microhematuria to chronic deterioration of renal function. We present a rare case of these two primary glomerulopathies concomitantly in one patient. This is intended to increase medical sensitivity in the diagnosis of the coexistence of these two primary glomerulopathies as atypical presentations in clinical practice.
References
Axelse, R. A., Crawford, D. H. G., Endre, Z. H., Lynch, S. V., Balderson, G. A., Strong, R. W., & Fleming, S. J. (1995). Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology, 27(3), 237–246. https://doi.org/10.1080/00313029500169053
Ballarín, J., Arce, Y., Marco, H., Da Silva, I., & Diaz, M. (2021). Nefropatía por Cambios Mínimos. Nefrología Al Día. http://www.revistanefrologia.com/es-monografias-nefrologia-dia-articulonefropatia-por-cambios-minimos-172
Barratt, J., & Feehally, J. (2006). Treatment of IgA nephropathy. Kidney International, 69(11), 1934–1938. https://doi.org/10.1038/sj.ki.5000419
Floege, J., Rauen, T., & Tang, S. C. W. (2021). Current treatment of IgA nephropathy. Seminars in Immunopathology, 43(5), 717–728. https://doi.org/10.1007/s00281-021-00888-3
Hernandez, M. E. (2021). Nefropatía IgA. Nefrologia Al Dia, 2659–2606. https://www.nefrologiaaldia.org/162
Liu, Y., Wei, W., Yu, C., Xing, L., Wang, M., Liu, R., Ma, J., Liu, X., Xie, R., & Sui, M. (2021). Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy. Medicina Clinica, 157(6), 267–273. https://doi.org/10.1016/j.medcli.2020.05.064
Lococo, B., Alberton, V., Fazzini, B., Quevedo, A., MoRales, D., & Malvar, A. (2016). Nefropatía por IgA. Revisión y conducta terapéutica a propósito de un caso clínico. Nefrología, Diálisis Y Trasplante, 36(2), 108–123. https://www.revistarenal.org.ar/index.php/rndt/article/viewFile/66/59
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012). Corticosteroid therapy in IgA nephropathy. Journal of the American Society of Nephrology, 23(6), 1108–1116. https://doi.org/10.1681/ASN.2011111112
Oberweis, B. S., Mattoo, A., Wu, M., & Goldfarb, D. S. (2013). Minimal Change Disease and IgA Deposition: Separate Entities or Common Pathophysiology? Case Reports in Nephrology, 2013, 1–3. https://doi.org/10.1155/2013/268401
Politano, S. A., Colbert, G. B., & Hamiduzzaman, N. (2020). Nephrotic Syndrome. Primary Care - Clinics in Office Practice, 47(4), 597–613. https://doi.org/10.1016/j.pop.2020.08.002
Pouria, S., & Feehally, J. (1999). Nephrology Dialysis Transplantation Glomerular IgA deposition in liver disease. Nephrology,Dialysis and Transplantation, 2279–2282. https://doi.org/10.1093/ndt/14.10.2279
Rajasekaran, A., Julian, B. A., & Rizk, D. V. (2021). IgA Nephropathy: An Interesting Autoimmune Kidney Disease: IgA Nephropathy. American Journal of the Medical Sciences, 361(2), 176–194. https://doi.org/10.1016/j.amjms.2020.10.003
Roberts, I. S. D., Cook, H. T., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., Bruijn, J. A., Cattran, D. C., Coppo, R., D’Agati, V., D’Amico, G., Emancipator, S., Emma, F., Feehally, J., Ferrario, F., Fervenza, F. C., Florquin, S., … Zhang, H. (2009). The Oxford
classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney International, 76(5), 546–556. https://doi.org/10.1038/ki.2009.168
Shima, Y., Nakanishi, K., Sato, M., Hama, T., Mukaiyama, H., Togawa, H., Tanaka, R., Nozu, K., Sako, M., Iijima, K., Suzuki, H., & Yoshikawa, N. (2017). IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatric Nephrology, 32(3), 457–465. https://doi.
org/10.1007/s00467-016-3502-6
Wang, J., Juan, C., Huang, Q., Zeng, C., & Liu, Z. (2013). Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: A single-centre cohort study. Nephrology Dialysis Transplantation, 28(9), 2339–2345. https://doi.org/10.1093/ndt/gft211